195 related articles for article (PubMed ID: 32283230)
1. Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations.
Blaszczak A; Trinidad JCL; Cartron AM
J Am Acad Dermatol; 2020 Jul; 83(1):e31. PubMed ID: 32283230
[No Abstract] [Full Text] [Related]
2. Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic.
Kearns DG; Chat VS; Uppal S; Wu JJ
J Am Acad Dermatol; 2020 Dec; 83(6):e433-e434. PubMed ID: 32735966
[No Abstract] [Full Text] [Related]
3. Remote management of hidradenitis suppurativa in a pandemic era of COVID-19.
Kang NC; Hsiao J; Shi V; Naik HB; Lowes MA; Alavi A
Int J Dermatol; 2020 Sep; 59(9):e318-e320. PubMed ID: 32578210
[No Abstract] [Full Text] [Related]
4. Clinical considerations for managing dermatology patients on systemic immunosuppressive or biologic therapy, or both, during the COVID-19 pandemic.
Sanchez DP; Kirsner RS; Lev-Tov H
J Am Acad Dermatol; 2020 Jul; 83(1):288-292. PubMed ID: 32380214
[No Abstract] [Full Text] [Related]
5. Global Hidradenitis Suppurativa COVID-19 Registry: a registry to inform data-driven management practices.
Naik HB; Alhusayen R; Frew J; Guilbault S; Ingram JR; Lowes MA; Marzano AV; Paul M; Villumsen B; Yannuzzi CA
Br J Dermatol; 2020 Oct; 183(4):780-781. PubMed ID: 32597495
[No Abstract] [Full Text] [Related]
6. Developing Covid-19 Vaccines at Pandemic Speed.
Lurie N; Saville M; Hatchett R; Halton J
N Engl J Med; 2020 May; 382(21):1969-1973. PubMed ID: 32227757
[No Abstract] [Full Text] [Related]
7. Keeping track of the SARS-CoV-2 vaccine pipeline.
Parker EPK; Shrotri M; Kampmann B
Nat Rev Immunol; 2020 Nov; 20(11):650. PubMed ID: 32989290
[TBL] [Abstract][Full Text] [Related]
8. The COVID-19 pandemic and the use of MS disease-modifying therapies.
Giovannoni G; Hawkes C; Lechner-Scott J; Levy M; Waubant E; Gold J
Mult Scler Relat Disord; 2020 Apr; 39():102073. PubMed ID: 32334820
[No Abstract] [Full Text] [Related]
9. [Not Available].
Nau JY
Rev Med Suisse; 2020 Jun; 16(696):1174-1175. PubMed ID: 32496708
[No Abstract] [Full Text] [Related]
10. The paramount importance of serological surveys of SARS-CoV-2 infection and immunity.
Goudsmit J
Eur J Epidemiol; 2020 Apr; 35(4):331-333. PubMed ID: 32318914
[No Abstract] [Full Text] [Related]
11. The Race to Develop a COVID-19 Vaccine.
Am J Nurs; 2020 Oct; 120(10):14-15. PubMed ID: 32976132
[TBL] [Abstract][Full Text] [Related]
12. Progress and Concept for COVID-19 Vaccine Development.
Wu SC
Biotechnol J; 2020 Jun; 15(6):e2000147. PubMed ID: 32304139
[No Abstract] [Full Text] [Related]
13. Multidisciplinary care of epidermolysis bullosa during the COVID-19 pandemic-Consensus: Recommendations by an international panel of experts.
Murrell DF; Lucky AW; Salas-Alanis JC; Woodley DT; Palisson F; Natsuga K; Nikolic M; Ramirez-Quizon M; Paller AS; Lara-Corrales I; Barzegar MA; Sprecher E; Has C; Laimer M; Bruckner AL; Bilgic A; Nanda A; Purvis D; Hovnanian A; Murat-Sušić S; Bauer J; Kern JS; Bodemer C; Martin LK; Mellerio J; Kowaleski C; Robertson SJ; Bruckner-Tuderman L; Pope E; Marinkovich MP; Tang JY; Su J; Uitto J; Eichenfield LF; Teng J; Aan Koh MJ; Lee SE; Khuu P; Rishel HI; Sommerlund M; Wiss K; Hsu CK; Chiu TW; Martinez AE
J Am Acad Dermatol; 2020 Oct; 83(4):1222-1224. PubMed ID: 32682031
[TBL] [Abstract][Full Text] [Related]
14. Chronic inflammatory skin diseases and biologics: what to expect after COVID-19 pandemic?
Megna M; Fabbrocini G; Marasca C
Int J Dermatol; 2020 Sep; 59(9):1144-1145. PubMed ID: 32710548
[No Abstract] [Full Text] [Related]
15. The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic.
Wan MT; Shin DB; Winthrop KL; Gelfand JM
J Am Acad Dermatol; 2020 Aug; 83(2):677-679. PubMed ID: 32416207
[No Abstract] [Full Text] [Related]
16. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines: Setting Expectations Appropriately.
Heininger U
Pediatr Infect Dis J; 2020 Jul; 39(7):e123-e124. PubMed ID: 32427644
[No Abstract] [Full Text] [Related]
17. Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic.
Yim RM; Singh I; Armstrong AW
Dermatol Online J; 2020 Oct; 26(10):. PubMed ID: 33147660
[TBL] [Abstract][Full Text] [Related]
18. Understanding COVID-19 vaccine efficacy.
Lipsitch M; Dean NE
Science; 2020 Nov; 370(6518):763-765. PubMed ID: 33087460
[No Abstract] [Full Text] [Related]
19. Coronavirus and Patients With Inflammatory Bowel Disease: Management Strategies for the Practicing Clinician.
Lichtenstein GR; Rubin DT
Am J Gastroenterol; 2020 Oct; 115(10):1566-1569. PubMed ID: 32833732
[No Abstract] [Full Text] [Related]
20. Is Gradual and Controlled Approach to Herd Protection a Valid Strategy to Curb the COVID-19 Pandemic?
Laxminarayan R; John TJ
Indian Pediatr; 2020 Jun; 57(6):505-507. PubMed ID: 32376793
[No Abstract] [Full Text] [Related]
[Next] [New Search]
